Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution

Vergoni, Anna Valeria; Tosi, Giovanni; Tacchi, Raffaella; Vandelli, Maria Angela; Bertolini, Alfio; Costantino, Luca

doi:10.1016/j.nano.2009.02.005

Cited by 129 publications

(78 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is widely believed that reducing the pulsatile stimulation of dopaminergic neurons will reduce the risk of levodopa-induced dyskinesia. 2 Use of nanotechnology in the medical science field and in nanomedicine has reached an advanced stage, where much research has been conducted on the synthesis of nanoparticles that can be used as delivery tools for anticancer agents, central nervous system tumor agents, 3,4 antibiotics, 5 and nonsteroidal anti-inflammatory drugs 6 in gene delivery and imaging studies. 7,8 Layered double hydroxides (LDHs), also known as hydrotalcite-like compounds or anionic clays, are a broad class of inorganic lamellar compounds with a high capacity for anion intercalation.…”

Section: Introductionmentioning

confidence: 99%

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Kura¹,

Ali²,

Hussein³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a direct coprecipitation method. The resulting nanocomposite was composed of the organic moiety, levodopa, sandwiched between Zn/Al-LDH inorganic interlayers. The basal spacing of the resulting nanocomposite was 10.9 Å. The estimated loading of levodopa in the nanocomposite was approximately 16% (w/w). A Fourier transform infrared study showed that the absorption bands of the nanocomposite were characteristic of both levodopa and Zn/Al-LDH, which further confirmed intercalation, and that the intercalated organic moiety in the nanocomposite was more thermally stable than free levodopa. The resulting nanocomposite showed sustained-release properties, so can be used in a controlled-release formulation. Cytotoxicity analysis using an MTT assay also showed increased cell viability of 3T3 cells exposed to the newly synthesized nanocomposite compared with those exposed to pure levodopa after 72 hours of exposure.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Kura¹,

Ali²,

Hussein³

et al. 2013

IJN

View full text Add to dashboard Cite

show abstract

“…brain) [17]. These capping agents can be varied in nature including polymers like polyethylene glycol (PEG) [16] and peptides [18].…”

Section: Introductionmentioning

confidence: 99%

Effect of surface coating on the biodistribution profile of gold nanoparticles in the rat

Morais

Soares

Duarte

et al. 2012

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

a b s t r a c tSuccessful application of gold nanoparticles (AuNPs) in biomedicine requires extensive safety assessment for which biokinetic studies are crucial.We evaluated the biodistribution of AuNPs ($20 nm) with different surface coatings: citrate, 11-MUA and 3 pentapeptides, CALNN, CALND and CALNS, after i.v. administration to rats (0.6-1 mg Au/kg). Biodistribution was evaluated based on Au tissue content measured by GFAAS.Citrate-AuNPs were rapidly removed from circulation with 60% of the injected dose depositing in the liver. Thirty minutes post-injection, the lungs presented about 6% of the injected dose with levels decreasing to 0.7% at 24 h. Gold levels in the spleen were of 2.6%. After 24 h, liver presented the highest Au level, followed by spleen and blood.A similar biodistribution profile was observed for MUA-coated AuNPs compared to Cit-AuNPs at 24 h post-injection, while significantly higher levels of peptide-capped AuNPs were found in the liver (74-86%) accompanied by a corresponding decrease in blood levels.TEM analysis of liver slices showed AuNPs in Kupffer cells and hepatocytes, trapped inside endosomes. Our data demonstrate that AuNPs are rapidly distributed and that the liver is the preferential accumulation organ. Peptide capping significantly increased hepatic uptake, showing the influence of AuNPs functionalization in biodistribution.

show abstract

“…Sialic acid derivative conjugated nanoparticles (Neu5Ac-PLGA502 NPs) : Initially, PLGA502H (50% lactic/50% glycolic acid ratio, inherent viscosity 0.20 dl/g, MW 4900; Boehringer-Ingelheim, Ingelheim am Rhein, Germany), selected as polymer on the basis of the yield of sugar conjugation, was conjugated with Neu5Ac (Sigma Aldrich), a sialic acid derivative, by applying the protocols previously reported [15,16]. Then, a mixture composed by Neu5Ac-PLGA502 (5 % w/w) and PLGA502H (95% w/w) was dissolved in acetone (8 mL).…”

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

AFM/TEM Complementary Structural Analysis of Surface-Functionalized Nanoparticles

Ruozi¹

2014

J Phys Chem Biophys

View full text Add to dashboard Cite

HighlightsShort collection of bullet points of the core article 1. Nanomedicine deserves interesting perspective for real application in medicine and surface modified nanocarriers represent the cutting-edge of nanomedicine.2. Aiming to the maximum translatability, surface-modified nanocarriers must be properly characterized, in terms of surface properties. Advanced microscopies (Atomic Force Microscopy andTransmission Electron Microscopy) help in better understanding of the chemico-physical features of nanocarriers 4. AFM and TEM give high resolution outcomes and should be chosen depending on specific the nature of surface-ligands 5. AFM allows to discriminate on the qualitative evaluation of ligands of different nature (QDs vs antibody) , without any additional treatment and without operating in a vacuum environment AbstractIn the field of nanomedicine, the characterization of functionalized drug delivery systems, introduced on market as efficacious and selective therapeutics, represents a pivotal aspect of great importance. In particular, the morphology of polymeric nanoparticles, the most studied nanocarriers, is frequently assessed by transmission electron microscopy (TEM). Despite of TEM high resolution and versatility, this technology is frequently hampered by both the complicated procedure for sample preparation and the operative condition of analysis. Considering the scanning probe microscopies, atomic force microscopy (AFM) represents an extraordinary tool for the detailed characterization of submicron-size structure as the surface functionalization at the atomic scale. In this paper we discussed the advantage and limits of these microscopies applied to the characterization of PLGA nanoparticles functionalized with three different kinds of ligands (carbohydrate ligand, an antibody and quantum dots crystals) intentionally designed, created and tailored with specific physico-chemical properties to meet the needs of specific applications (targeting or imaging). quantum dots (QD) to obtain double imaging/drug release (theranostic aim). If compared with the encapsulation process, the conjugation and the exposure of QD on NPs surface is preferred in order to avoid the QD release and to ensure the optimal imaging [12,13]. Graphical Abstract PEG-QDs Materials and Methods Preparation of nanoparticlesAll NPs analysed were obtained according to the nanoprecipitation procedure [14]. The functionalization can be inserted during NPs formulation by using polymer previously modified (Neu5Ac-PLGA502) or after the NPs formation by activating the functional groups onto NPs surfaces by "in situ" reaction and subsequent conjugation with ligands (Rituximab-PLGA503 NP and QD-PLGA503 NPs).Sialic acid derivative conjugated nanoparticles (Neu5Ac-PLGA502 NPs) : Initially, PLGA502H (50% lactic/50% glycolic acid ratio, inherent viscosity 0.20 dl/g, MW 4900; Boehringer-Ingelheim, Ingelheim am Rhein, Germany), selected as polymer on the basis of the yield of sugar conjugation, was conjugated with Neu5Ac (Sigma Aldrich), a sialic acid...

show abstract

Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution

Cited by 129 publications

References 36 publications

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent

Effect of surface coating on the biodistribution profile of gold nanoparticles in the rat

AFM/TEM Complementary Structural Analysis of Surface-Functionalized Nanoparticles

Contact Info

Product

Resources

About